Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib Long-term Follow-up in Hematologic Malignancies
NCT02711852Phase 2Completed
- Sponsor
- Secura Bio
- Start
- Apr 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in hematologic malignancy, sponsored by Secura Bio. Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events up to 45 months. Started Apr 2016; status: completed.
02
Drugs
duvelisib
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02711852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711852.